Clinical trial
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to…
NCT03517566 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT03517566 |
|---|---|
| Title | A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis |
| Official title | A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atopic Dermatitis |
| Intervention type | Drug |
| Interventions | Placebo, ZPL389 3mg, ZPL389 10mg, ZPL389 30mg, ZPL389 50mg |
| Enrollment | 293 |
| Start date | Nov 14, 2018 |
| Primary completion | Jul 15, 2020 |
| Completion | Aug 6, 2020 |
| First posted | May 7, 2018 |
| Last update posted | Oct 8, 2021 |
| Countries | Austria, Belgium, Canada, Czechia, Finland, Germany, Hungary, Iceland, Japan, Netherlands, Poland, Russia and 4 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: